• Lineage Cell Therapeutics will advance hearing-loss cell therapy ReSonance into its collaboration’s second year, having completed all planned first-year development activities.
• Manufacturing yielded the first clinical-grade cGMP batch and three engineering batches, completing technology transfer from research to the cGMP team.
• Researchers established a deafening model to support functional preclinical testing of the therapy, which targets auditory nerve degeneration.
• A Danish Medicines Agency meeting is planned for the fourth quarter of 2026 to review development plans and seek scientific advice.
• Partner William Demant Invest committed up to $12 million for research collaboration costs over three years beginning August 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261029584817) on October 29, 2026, and is solely responsible for the information contained therein.